Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection
Open accessPublished version of a preprint
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; none of the 52 sources its claims cite is checked for support yet.
Abstract
Gene editing is now routine in all prokaryotic and metazoan cells but has not received much attention in immune cells when the CRISPR-Cas9 technology was introduced in the field of mammalian cell biology less than ten years ago. This versatile technology has been successfully adapted for gene modifications in human myeloid cells and T cells, among others, but applications to human primary B cells have been scarce and limited to activated B cells. This limitation has precluded conclusive studies into cell activation, differentiation or cell cycle control in this cell type. We report on highly efficient, simple and rapid genome engineering in primary resting human B cells using nucleofection of Cas9 ribonucleoprotein complexes, followed by EBV infection or culture on CD40 ligand feeder cells to drive in vitro B cell survival. We provide proof-of-principle of gene editing in quiescent human B cells using two model genes: CD46 and CDKN2A . The latter encodes the cell cycle regulator p16 INK4a which is an important target of Epstein-Barr virus (EBV). Infection of B cells carrying a knockout of CDKN2A with wildtype and EBNA3 oncoprotein mutant strains of EBV allowed us to conclude that EBNA3C controls CDKN2A , the only barrier to B cell proliferation in EBV infected cells. Together, this approach enables efficient targeting of specific gene loci in quiescent human B cells supporting basic research as well as immunotherapeutic strategies.
Overview
CoChat Summary
TL;DR
The paper reports a nucleofection protocol for delivering Cas9 ribonucleoproteins into resting primary human B cells, achieving CD46 knockout in >85% of cells and enabling functional studies of Epstein-Barr virus infection. Using this approach, the authors confirm that EBNA3C represses CDKN2A/p16INK4a as a barrier to EBV-driven B cell proliferation, but do not find evidence that EBNA3A/C block plasma cell differentiation in newly infected primary B cells.
Key findings
- Nucleofection of two CD46-Cas9 RNPs into primary human B cells yielded ~60% knockout with individual gRNAs and regularly ≥85% with both, at DNA and CD46 surface-protein levels; viability was typically 70–80%. Comparable CD46 knockout was obtained from PBMC-derived B cells and with CD40L/IL-4 expansion, and editing did not require EBV infection.
- In non-infected B cells, CD46 indel frequency was >70% at 16 h and up to 85% at 72 h; in EBV-infected cells, knockout reached 60% at 24 h and plateaued at ~85%, with CD46-negative cells rising from ~10% at 24 h to >85% at day 8. At 24 h after nucleofection, 47.8% of CD46 exon 2 RNA reads were unaltered, 17.6% had mutations, and 34.6% had ~98-nt deletions; CD46 transcription was reduced 0.73-fold, with no major global transcriptome impact and no detectable IFN-α release.
- Targeting CDKN2A exon1α gave knockout efficiency ~60–80%. In mixed cultures (10–20% p16 KO initially), ΔEBNA3C EBV-infected cells showed gradual enrichment of CDKN2A-negative cells exceeding 80% after 8 weeks, whereas WT EBV-infected populations did not show a clear trend. p16INK4a-negative cells infected with ΔEBNA3C EBV continued to proliferate beyond ~5–6 weeks, while p16-positive cells ceased to proliferate and died.
- In p16 KO cells infected with ΔEBNA3A/C EBV, flow cytometry after up to two months showed no substantial differences in CD20, CD38, and CD138 versus WT EBV-infected controls; CD138 differences were significant but very low and no CD138high subpopulation was seen, so the authors did not recapitulate EBNA3A/C blockade of plasma cell differentiation.
Methods
- Primary human B cells were isolated from adenoid biopsies or PBMCs/buffy coats; 2×10^6 cells were nucleofected with in vitro assembled Cas9 RNPs (tracrRNA/crRNA plus S. pyogenes Cas9 V3) using Lonza P3 buffer and the EH100 program, then infected with WT or mutant EBV (6008, 6123 ΔEBNA3C, 6331 ΔEBNA3A/C) at MOI 0.1 green Raji units or cultured on CD40L feeder cells with IL-4.
- Knockout was quantified by next-generation sequencing of PCR amplicons analyzed with Outknocker 2.0; surface protein and immunophenotype by flow cytometry; newly transcribed RNA by 4sU labeling and RNA-seq on NextSeq500 (2×150 bp, 15.7–18.6 million reads/sample); IFN-α by ELISA. Statistics used Prism v7.0, Wilcoxon signed-rank test, and one-way ANOVA where indicated.
- For CDKN2A experiments, WT and p16 KO cells were mixed at 10–20% KO, infected with WT or ΔEBNA3C EBV, and tracked by NGS and cell expansion; differentiation markers CD20/CD38/CD138 were compared with WT EBV-infected controls and RPMI-8226 as positive control.
Limitations
- Stated: the paper notes that overall RNA yield from 4sU labeling was very low, although quality control confirmed high-quality libraries; it also states that the specific gene locus and gRNA design may strongly affect outcome, and that some GO/GSEA results were less conclusive.
- Stated: the paper reports that its results with newly infected primary B cells appear to differ from previous work on EBNA3A/C-mediated blockade of plasma cell differentiation, and it does not recapitulate that phenotype; the reason is stated as unknown.
- Evident from the text: long-term editing readouts depend on EBV infection or CD40L/IL-4 culture to prevent rapid apoptosis of primary B cells, so editing in truly resting B cells without such survival support was not assessed; some experiments (e.g., IFN-α ELISA, one CDKN2A time course) used two biological replicates, and transcriptome analysis used three donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
0 Valid · 0 Not valid · 40 Not checked · 69 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We provide proof-of-principle of gene editing in quiescent human B cells using two model genes: CD46 and CDKN2A.”
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We report on highly efficient, simple and rapid genome engineering in primary resting human B cells using nucleofection of Cas9 ribonucleoprotein complexes, followed by EBV infection or culture on CD40 ligand feeder cells to drive in vitro B cell survival.”
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When both CD46-Cas9 RNP complexes were co-nucleofected knockout efficiencies regularly reached 85% and more both at the level of DNA editing and loss of CD46 surface expression (Figs 1B and 1C and S1A).”
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Results > CRISPR-Cas9 efficiently targets the locus of the cell surface protein CD46 in primary human B cells
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Already 24 hours after Cas9 RNP complex nucleofection more than 50% of newly transcribed CD46 mRNAs contained indels or showed the characteristic deletion in exon 2 (Fig 2G)”
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In a counterexample, our experiments did not recapitulate the function of two viral transcriptional repressors, EBNA3A and EBNA3C, which were reported to block terminal differentiation of mature B cells into plasmablasts or plasma cells [17].”
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Introduction
What the sources say
- Not checked yetcites [17] CT Styles, 2017, EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency, PLoS Biol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
50 more claims
Create a free account to see all 109 claims and to verify the 52 references still open.
- It may state two separate claims as one. 36
- Probably not a substantial claim. 19
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Methods > Statistical analysis
“Data are reported as mean and SEM.”
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Results > CRISPR-Cas9 efficiently targets the locus of the cell surface protein CD46 in primary human B cells
“Mean and standard deviation from four independent biological replicates are shown.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Results > EBNA3C controls CDKN2A, a barrier to B cell proliferation
“The knockout status of the CDKN2A gene was studied by next generation sequencing to analyze the CD46 locus of the mixed cell populations over time.”
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Results > EBNA3C controls CDKN2A, a barrier to B cell proliferation
“Occasionally, cells were sampled and their cellular DNAs were analyzed for CDKN2A knockout frequencies by next generation sequencing.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Results > The kinetics of induced DNA breaks and their repair in non-infected and EBV infected primary B cells
“We achieved more than 70% indel frequency in primary human B cells 16 h after nucleofection and up to 85% 72h after nucleofection”
§ Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection > Results > The kinetics of induced DNA breaks and their repair in non-infected and EBV infected primary B cells
“Indel frequencies increased up to 90% 72 h after nucleofection.”
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
MultiQC: summarize analysis results for multiple tools and samples in a single report
Ewels, P., Magnusson, M., Lundin, S., & Käller, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw354 · Cited by 10,143
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
DNA interrogation by the CRISPR RNA-guided endonuclease Cas9
Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C., & Doudna, J. A. (2014) · Nature · doi:10.1038/nature13011 · Cited by 1,822
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
The generation of antibody-secreting plasma cells
Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M., & Corcoran, L. M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3795 · Cited by 1,454
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090 · cited 1×
“nuclease with synthetic CRISPR RNA (crRNA) and trans-activating CRISPR RNA (tracrRNA) followed by nucleofection of the ribonucleoprotein (RNP) complex directly into cells was a major breakthrough in the T cell field [4,5].”
MethodGeneration of knock-in primary human T cells using Cas9 ribonucleoproteins
Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702
ArrayExpress update—simplifying data submissions
Kolesnikov, N., Hastings, E., Keays, M., Melnichuk, O., Tang, Y. A., Williams, E., Dylag, M., Kurbatova, N., Brandizi, M., Burdett, T., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1057 · Cited by 698
CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA)
Pulvertaft, R. J. V. (1964) · The Lancet · doi:10.1016/s0140-6736(64)92345-1 · Cited by 626
Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meissner, T. B., Boutwell, C. L., Friesen, M., Vrbanac, V., Garrison, B. S., Stortchevoi, A., Bryder, D., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.10.004 · Cited by 475 · cited 1×
“Early studies that applied CRISPR-Cas9 mediated gene editing in primary human T cells resulted in low targeting efficiencies and cellular toxicity [2,3] probably due to the delivery of the Cas9 encoding plasmid DNA together with the two indispensable RNAs to assemble a functional CRISPR-Cas9 complex in the cells.”
BackgroundSeki, A., & Rutz, S. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171626 · Cited by 372
Matsuoka, Y., Moore, G. E., Yagi, Y., & Pressman, D. (1967) · Experimental Biology and Medicine · doi:10.3181/00379727-125-32327 · Cited by 287
Targeted Cell Entry of Lentiviral Vectors
Funke, S., Maisner, A., Mühlebach, M. D., Koehl, U., Grez, M., Cattaneo, R., Cichutek, K., & Buchholz, C. J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.128 · Cited by 218
Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection
Mrozek-Gorska, P., Buschle, A., Pich, D., Schwarzmayr, T., Fechtner, R., Scialdone, A., & Hammerschmidt, W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901314116 · Cited by 210
Self-citationGlycoprotein gp110 of Epstein–Barr virus determines viral tropism and efficiency of infection
Neuhierl, B., Feederle, R., Hammerschmidt, W., & Delecluse, H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232381299 · Cited by 187
Self-citationHultquist, J. F., Schumann, K., Woo, J. M., Manganaro, L., McGregor, M. J., Doudna, J., Simon, V., Krogan, N. J., & Marson, A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.080 · Cited by 170
Clarke, R., Heler, R., MacDougall, M. S., Yeo, N. C., Chavez, A., Regan, M. R., Hanakahi, L. A., Church, G. M., Marraffini, L. A., & Merrill, B. J. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.005 · Cited by 163
OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines
Schmid-Burgk, J. L., Schmidt, T., Gaidt, M. M., Pelka, K., Latz, E., Ebert, T. S., & Hornung, V. (2014) · Genome Research · doi:10.1101/gr.176701.114 · Cited by 139
Skalska, L., White, R. E., Franz, M., Ruhmann, M., & Allday, M. J. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000951 · Cited by 136
Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells
Hung, K. L., Meitlis, I., Hale, M., Chen, C.-Y., Singh, S., Jackson, S. W., Miao, C. H., Khan, I. F., Rawlings, D. J., & James, R. G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.012 · Cited by 134
The LL-100 panel: 100 cell lines for blood cancer studies
Quentmeier, H., Pommerenke, C., Dirks, W. G., Eberth, S., Koeppel, M., MacLeod, R. A. F., Nagel, S., Steube, K. G., Uphoff, C. C., & Drexler, H. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-44491-x · Cited by 126
First days in the life of naive human B lymphocytes infected with Epstein-Barr virus.
Pich, D., Mrozek-Gorska, P., Bouvet, M., Sugimoto, A., Akidil, E., Grundhoff, A., Hamperl, S., Ling, P. D., & Hammerschmidt, W. (2019) · mBio · doi:10.1128/mbio.01723-19 · Cited by 112
Self-citationConditional Immortalization of Human B Cells by CD40 Ligation
Wiesner, M., Zentz, C., Mayr, C., Wimmer, R., Hammerschmidt, W., Zeidler, R., & Moosmann, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001464 · Cited by 108
Self-citationMaruo, S., Wu, Y., Ishikawa, S., Kanda, T., Iwakiri, D., & Takada, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604919104 · Cited by 96
Kempkes, B., Pich, D., Zeidler, R., Sugden, B., & Hammerschmidt, W. (1995) · Journal of Virology · doi:10.1128/jvi.69.1.231-238.1995 · Cited by 94
Self-citationEngineering of Primary Human B cells with CRISPR/Cas9 Targeted Nuclease
Johnson, M. J., Laoharawee, K., Lahr, W. S., Webber, B. R., & Moriarity, B. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-30358-0 · Cited by 92
Genetic modification of primary human B cells to model high-grade lymphoma
Caeser, R., Re, M. D., Krupka, J. A., Gao, J., Lara‐Chica, M., Dias, J. M. L., Cooke, S. L., Fenner, R. E., Usheva, Z., Runge, H. F. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12494-x · Cited by 90
Immunophenotype of normal and myelomatous plasma-cell subsets
Robillard, N., Wuillème, S., Moreau, P., & Béné, M. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00137 · Cited by 82
Styles, C. T., Bazot, Q., Parker, G. A., White, R. E., Paschos, K., & Allday, M. J. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001992 · Cited by 78
Skalska, L., White, R. E., Parker, G. A., Sinclair, A. J., Paschos, K., & Allday, M. J. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003187 · Cited by 77
Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system
Cheong, T.-C., Compagno, M., & Chiarle, R. (2016) · Nature Communications · doi:10.1038/ncomms10934 · Cited by 73
Bouvet, M., Voigt, S., Tagawa, T., Albanese, M., Chen, Y.-F. A., Chen, Y., Fachko, D. N., Pich, D., Göbel, C., Skalsky, R. L., et al. (2021) · mBio · doi:10.1128/mbio.03440-20 · Cited by 62
Self-citationFunke, S., Schneider, I. C., Glaser, S., Mühlebach, M. D., Moritz, T., Cattaneo, R., Cichutek, K., & Buchholz, C. J. (2009) · Gene Therapy · doi:10.1038/gt.2009.11 · Cited by 58
Genetic engineering in primary human B cells with CRISPR-Cas9 ribonucleoproteins
Wu, C.-A. M., Roth, T. L., Baglaenko, Y., Ferri, D. M., Brauer, P., Zuniga-Pflucker, J. C., Rosbe, K. W., Wither, J. E., Marson, A., & Allen, C. D. C. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.03.009 · Cited by 57
Isolation of Newly Transcribed RNA Using the Metabolic Label 4-Thiouridine
Garibaldi, A., Carranza, F., & Hertel, K. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7204-3_13 · Cited by 53
Maier, S., Šantak, M., Mantik, A., Grabušić, K., Kremmer, E., Hammerschmidt, W., & Kempkes, B. (2005) · Journal of Virology · doi:10.1128/jvi.79.14.8784-8792.2005 · Cited by 49
Self-citationSteinbrück, L., Gustems, M., Medele, S., Schulz, T. F., Lutter, D., & Hammerschmidt, W. (2015) · Journal of Virology · doi:10.1128/jvi.00839-15 · Cited by 46
Self-citationCD46-induced human Treg enhance B-cell responses
Fuchs, A., Atkinson, J. P., Fremeaux‐Bacchi, V., & Kemper, C. (2009) · European Journal of Immunology · doi:10.1002/eji.200939392 · Cited by 42
The cooperative functions of the EBNA3 proteins are central to EBV persistence and latency
Styles, C., Paschos, K., White, R., & Farrell, P. (2018) · Pathogens · doi:10.3390/pathogens7010031 · Cited by 41
Immortalization of human primary B lymphocytes in vitro with DNA
Kempkes, B., Pich, D., Zeidler, R., & Hammerschmidt, W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.5875 · Cited by 40
Self-citationAllday, M. J., Bazot, Q., & White, R. E. (2015) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-319-22834-1_3 · Cited by 27
Paíno, T., Sarasquete, M. E., Paiva, B., Krzeminski, P., San-Segundo, L., Corchete, L. A., Redondo, A., Garayoa, M., García-Sanz, R., Gutiérrez, N. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092378 · Cited by 22
Hellebrand, E., Mautner, J., Reisbach, G., Nimmerjahn, F., Hallek, M., Mocikat, R., & Hammerschmidt, W. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302602 · Cited by 18
Self-citationEfficient somatic gene targeting in the lymphoid human cell line DG75
Feederle, R., Delecluse, H., Rouault, J.-P., Schepers, A., & Hammerschmidt, W. (2004) · Gene · doi:10.1016/j.gene.2004.08.005 · Cited by 18
Self-citationFlow Cytometry Assessment of In Vitro Generated CD138+Human Plasma Cells
Itoua Maïga, R., Lemieux, J., Roy, A., Simard, C., & Néron, S. (2014) · BioMed Research International · doi:10.1155/2014/536482 · Cited by 8
Cited by
CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells
Bloomer, H., Khirallah, J., Li, Y., & Xu, Q. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114087 · Cited by 78
CRISPR innovations in tissue engineering and gene editing
Razavi, Z.-S., Soltani, M., Souri, M., & van Wijnen, A. J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123120 · Cited by 53
A comprehensive overview of CRISPR/Cas 9 technology and application thereof in drug discovery
Khurana, A., Sayed, N., Singh, V., Khurana, I., Allawadhi, P., Rawat, P. S., Navik, U., Pasumarthi, S. K., Bharani, K. K., & Weiskirchen, R. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30329 · Cited by 29
Gene-Editing and RNA Interference in Treating Hepatitis B: A Review
Kasianchuk, N., Dobrowolska, K., Harkava, S., Bretcan, A., Zarębska‐Michaluk, D., Jaroszewicz, J., Flisiak, R., & Rzymski, P. (2023) · Viruses · doi:10.3390/v15122395 · Cited by 27
SoRelle, E. D., Reinoso-Vizcaíno, N. M., Dai, J., Barry, A. P., Chan, C. C. W., & Luftig, M. A. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112958 · Cited by 24
Metadata
- Authors
- Akidil, E., Albanese, M., Buschle, A., Ruhle, A., Pich, D., Keppler, O. T., & Hammerschmidt, W.
- Affiliations
- Helmholtz Munich (DE)
- German Center for Infection Research (DE)
- Corresponding author
- Hammerschmidt, Wolfgang
- ORCID
- Venue
- PLOS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-04-15
- Volume
- 17
- Issue
- 4
- Pages
- e1009117
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC8078793
- OpenAlex
- W3155357417
- Cited by
- 31
- References
- 51
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 6 · 2022: 8 · 2021: 3
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Update notices
- new_version (2021-04-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- Site cant be reached (submittedVersion, cc-by)
- Funders
- Deutsche Krebshilfe (70112875)
- Deutsches Zentrum für Infektionsforschung (07.814)
- Deutsche Forschungsgemeinschaft (SFB1064/TP A13)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, gene knockout, Epstein-Barr virus infection, nucleofection, Cas9 ribonucleoprotein, resting B cells, CDKN2A, p16INK4a, EBNA3C, CD46, B cell proliferation
- MeSH terms
- Gene Editing, B-Lymphocytes, Herpesvirus 4, Human, Humans, Lymphocyte Activation, Viral Proteins, Virus Latency, Epstein-Barr Virus Nuclear Antigens, Epstein-Barr Virus Infections, Gene Knockout Techniques, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.